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Background: Oxaliplatin, a widely used anticancer drug against metastatic colorectal cancer, can induce acute
peripheral neuropathy, which is characterized by cold and mechanical allodynia. Activation of glial cells (e.g. astrocytes
and microglia) and increase of pro-inflammatory cytokines (e.g. IL-1β and TNF-α) in the spinal cord play a crucial role in
the pathogenesis of neuropathic pain. Our previous study demonstrated that Gyejigachulbu-Tang (GBT), a herbal complex
formula, alleviates oxaliplatin-induced neuropathic pain in rats by suppressing spinal glial activation. However, it remains
to be elucidated whether and how Buja (Aconiti Tuber), a major ingredient of GBT, is involved in the efficacy of GBT.
Methods: Cold and mechanical allodynia induced by an oxaliplatin injection (6 mg/kg, i.p.) in Sprauge-Dawley rats were
evaluated by a tail immersion test in cold water (4 °C) and a von Frey hair test, respectively. Buja (300 mg/kg) was orally
administrated for five consecutive days after the oxaliplatin injection. Glial activation in the spinal cord was quantified by
immunohistochemical staining using GFAP (for astrocytes) and Iba-1 (for microglia) antibodies. The amount of spinal
pro-inflammatory cytokines, IL-1β and TNF-α, were measured by ELISA.
Results: Significant behavioral signs of cold and mechanical allodynia were observed 3 days after an oxaliplatin injection.
Oral administration of Buja significantly alleviated oxaliplatin-induced cold and mechanical allodynia by increasing the tail
withdrawal latency to cold stimuli and mechanical threshold. Immunohistochemical analysis showed the activation of
astrocytes and microglia and the increase of the IL-1β and TNF-α levels in the spinal cord after an oxaliplatin injection.
Administration of Buja suppressed the activation of spinal astrocytes without affecting microglial activation and down-
regulated both IL-1β and TNF-α levels in the spinal cord.
Conclusions: Our results indicate that Buja has a potent anti-allodynic effect in a rat model of oxaliplatin-induced
neuropathic pain, which is associated with the inhibition of activation of astrocytes and release of pro-inflammatory
cytokines in the spinal cord. Thus, our findings suggest that administration of Buja could be an alternative therapeutic
option for the management of peripheral neuropathy, a common side-effect of oxaliplatin.
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Oxaliplatin is a third-generation platinum-based chemo-
therapy drug, which is widely used as the first-line treat-
ment of metastatic colorectal cancer [1–5]. Despite its
efficacy against the tumor, it has serious neurotoxicity, a
dose-limiting side effect. This neurotoxicity is character-
ized by paresthesia and dysesthesia in the hands and feet
[6], and about 85 to 95% of patients rapidly develop
significant acute neuropathic pain without motor dys-
function shortly after an oxaliplatin infusion [7, 8].
Several drugs (e.g. gabapentin and duloxetine) are
recommended to mitigate this side effect [9–11]. Unfor-
tunately, these analgesics cause another side effects, such
as somnolence and nausea [12].
Activation of glial cells, such as astrocytes and micro-
glia, has been observed in the lumbar spinal cord in ani-
mal models of peripheral neuropathic pain [13–17].
Upon activation, astrocytes and microglia release a var-
iety of substances that enhance the transmission of pain,
such as pro-inflammatory cytokines [18, 19]. Both inter-
leukin (IL)-1β and tumor necrosis factor-α (TNF-α) en-
hance the spontaneous excitatory post-synaptic currents
frequency of spinal dorsal horn neurons [20]. In animal
models of chemotherapy-induced peripheral neuropathy
(CIPN), the causal relationship between glial activation
and neuropathic pain has also been reported [21–24].
Oxaliplatin treatment lowered the pain threshold com-
bined with a significant increase in the number of GFAP
(astrocyte) and Iba-1 (microglia) immunoreactive cells in
the spinal dorsal horn [21, 22]. In addition, a single in-
jection of oxaliplatin induces spinal glial activation coin-
cident with pain behaviors like cold and mechanical
allodynia [25].
Buja, a processed Aconiti tuber, is one of the fre-
quently used herbal medicine in several diseases
[25–27]. Previous articles have reported its analgesic effect
on different kinds of neuropathic pain, such as diabetic
neuropathy and postherpetic neuralgia [28, 29]. Buja
inhibited neuropathic mechanical allodynia by suppressing
the activation of spinal astrocytes in a nerve injury model
[26]. Also, a recent clinical study has reported that Buja
reduced neuropathic pain in oxaliplatin-treated colorectal
cancer patients [30]. Gyejigachulbu-tang (GBT), which is
composed of Cinnamomi Cortex (Yukgye; in Korean),
Peoniae Radix (Jakyak), Atractylodis Lanceae Rhizoma
(Bokryeng), Ziziphi Fructus (Saenggang), Glycyrrhizae
Radix (Gamcho), Zingiberis Rhizoma (Gungang) and
Aconiti Tuber (Buja), showed a potent analgesic effect
against oxaliplatin-induced peripheral neuropathy in rats.
Such effect of GBT is associated with deactivation of
spinal astrocytes and microglia [25].
In the present study, we investigated whether Buja re-
lieves oxaliplatin-induced cold and mechanical allodynia
in rats, and if so, whether such anti-allodynic effect ofBuja is related to the modulation of glial activation and
pro-inflammatory cytokines in the spinal cord.
Methods
Animals
Young adult male Sprague-Dawley rats (Daehan Biolink,
Chungbuk, Korea), weighing approximately 200–220 g,
at the beginning of the experimental procedure were
used. Animals were housed in cages (3–4 rats per cage),
and fed with water and food ad libitum. The room was
maintained with a 12 h-light/dark cycle (a light cycle;
08:00–20:00, a dark cycle; 20:00–08:00) and kept at
23 ± 2 °C. All animals were acclimated in their cages
for 1 week prior to any experiments. All procedures
involving animals were approved by the Institutional
Animal Care and Use Committee of Kyung Hee
University (KHUASP(SE)-15-088) and were conducted
in accordance with the guidelines of the International
Association for the Study of Pain [31].
Drug administration
Oxaliplatin (Sigma-Aldrich, St Louis, MO, USA) was
delivered at an amount of 6 mg/kg [32, 33], dissolved in
5% glucose (Sigma-Aldrich) solution at a concentration
of 2 mg/ml. Oxaliplatin was administered intraperitone-
ally (i.p.). Control animals received an equivalent volume
of 5% glucose solution i.p. as a vehicle.
Buja (Bushi in Japanese; TJ-3023, Tsumura Co. Ltd.,
Ibaraki, Japan) was obtained by a generous gift from
Prof. Schuichi Koizumi (Department of Neuropharma-
cology, Faculty of medicine, University of Yamanashi).
The quality of Buja is strictly controlled by the manufac-
turer. Buja was suspended and diluted with distilled
water (30 mg/ml, 300 mg/kg, approximately 2–2.2 ml/
rat) [26]. Our preliminary study using several doses of
Buja confirmed that 300 mg/kg was the optimal concen-
tration. Buja was treated orally for 5 consecutive days
after an oxaliplatin injection. Equivalent volume of dis-
tilled water (DW) was administered to control animals.
Animals were arbitrarily divided into 4 groups: Vehicle +
DW, group1; Vehicle + Buja, group2; Oxaliplatin +DW,
group3; Oxaliplatin + Buja; group4.
Behavioral tests
For assessment of oxaliplatin-induced neuropathic pain
before and after Buja administraion, cold and mechan-
ical test were performed. Cold allodynia were deter-
mined by cold immersion test as previously described
[34, 35]. In brief, rats were placed into an acrylic cylin-
der holder with the tail protruding and were adapted to
the testing environment at least 30 min prior to testing.
After immersing the tail in 4 °C water, the tail with-
drawal latency (TWL) was measured with a 15 s cut-off
time. This test was repeated 5 times at 5 min intervals
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was used to represent cold allodynia (i.e. the shorter
latency was considered the more severe cold allodynia).
Mechanical allodynia was evaluated the withdrawal re-
sponse of tail using a series of von Frey filaments (bend-
ing forces to 0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0 and 15.0 g;
equivalent in log units: 3.61, 3.84, 4.08, 4.31, 4.56, 4.74,
4.93 and 5.18; Stoelting, IL, USA), as previously
described [25]. Using the up-down method, the 50%
withdrawal threshold was determined [36]. Rats were
immobilized in an acrylic cylinder holder as mentioned
above. Test was initiated with a filament having 2.0 g
bending force. When withdrawal of the tail was observed
during or right after stimulation, this was considered as
a positive response. The filament with the next lower
bending force was applied after a positive response was
observed, whereas the filament with the next higher
bending force was applied when there was no response
(i.e. negative response). This procedure continued until
the sixth von Frey filament stimulation from the first
stimulation (2.0 g) or until the third change of response
(positive or negative) was observed. The extreme values
of series of von Frey filaments were set as a cut-off
value. These responses were converted into 50%
threshold value using the following formula: 50%
threshold = Xf + κδ (Xf is the value of the final von
Frey filament [log units], κ is the correction factor
from calibration table, and δ is the mean difference
of log units between stimuli) [37].
Immunohistochemistry
At the end of the experiment (day 5), the L4/L5 seg-
ments of the spinal cord were exposed from the lumbar
vertebral column via laminectomy and identified by tra-
cing the dorsal roots from their respective dorsal root
ganglia (DRG). Animals were perfused using 0.1 M
phosphate buffered saline (PBS), followed by 4% parafor-
maldehyde (BBC Biochemical, WA, USA). Sampled
tissues were post-fixed in 4% paraformaldehyde (BBC
Biochemical) for 24 h at 4 °C, and then permeated with
30% sucrose (Sigma-Aldrich) in 0.1 M PBS for 48 h at
4 °C. Lumbar spinal cord segments were embedded in
optimal cutting temperature (OCT) compound (Sakura
Finetek, Tokyo, Japan) on dry ice. Using cryostat
(Microm HM 505N; Thermo Scientific, MA, USA),
frozen spinal cord segments were cut at a 20 μm thick-
ness. Sections were collected in 0.1 M PBS at 4 °C.
These sections were mounted on slide glass (Matsunami,
Osaka, Japan) and incubated for 1 h in 0.2% Triton
X-100 in 0.5% bovine serum albumin (BSA; BOVOGEN
biologics, East Keilor, Australia) solution at room
temperature (RT). After rinsing the slide glass with 0.5%
BSA solution, double immunostaining using primary
antibodies raised in different species was carried out.The sections were incubated overnight at 4 °C with pri-
mary antibodies: mouse anti-glial fibrillary acidic protein
(GFAP 1:500; Millipore, CA, USA), rabbit anti-Iba-1
(1:500; Wako, Osaka, Japan). After rinsing in 0.5% BSA
solution, sections were incubated at RT in dark for 1 h
with secondary antibodies: anti-mouse and anti-rabbit-
immunoglobulin G (IgG) labeled with Alexa Fluor 488
and Alexa Fluor 546 (1:200; Invitrogen, USA). Confocal
laser microscope (LSM 5 Pascal, Zeiss, Oberkochen,
Germany) was used to obtain immunofluorescent im-
ages. Quantitative analysis of GFAP and Iba-1 positive
cells were performed on the spinal dorsal horn images
taken through a 20X 0.5NA objective. ImageJ (https://
imagej.nih.gov/ij/, National Institutes of Health, USA)
was used for quantifying the GFAP positive cells and
Iba-1 positive cells [22]. To quantify GFAP or Iba-1
positive cells, number of GFAP or Iba-1 positive cells
from six lumbar spinal cord section images of each
animal were averaged. Six animals were allocated in
each group.
ELISA
To investigate whether Buja administration decreases
the quantity of TNF-α or IL-1β in the spinal cord, each
cytokine was measured by enzyme linked immunosorb-
ent assay (ELISA). The animals were sacrificed at the
end of the experiment. After perfusion with 0.1 M PBS,
the lumbar spinal cord segments were obtained as de-
scribed above. Every collected tissue was stored in 1 ml
RIPA buffer (Thermo Scientific) with protease inhibitor
cocktail (Roche, Basel, Switzerland). Samples were
assayed using a commercial rat TNF (BD OptEIA Set
Rat TNF, BD biosciences, CA, USA) and mouse IL-1β
(BD OptEIA Set mouse IL-1β, BD biosciences) ELISA
kit following the manufacturer’s protocol. In brief, 1:10
dilution of serum was used for the quantification of both
cytokines. Microtiter plates were coated overnight at 4 °C
with anti-rat TNF or anti-mouse IL-1β monoclonal anti-
bodies (mAbs). Each well was blocked with 10% fetal bo-
vine serum (FBS; Gibco, Thermo Scientific) for 1 h at RT.
Samples and standards were loaded after washing out FBS
and incubated for 2 h at RT. Biotinylated anti-rat TNF
and anti-mouse IL-1β mAbs were added for 1 h at RT.
Streptavidin-horseradish peroxidase conjugate was treated
and incubated for 30 min. TMB substrate solution (BD
Bioscience) was treated for 30 mins, and then Stop solu-
tion was added. Washing each well with PBST (PBS with
Tween-20; Sigma-Aldrich) was performed between every
step. Optical density (O.D.) was measured at 450 nm with
λ correction 570 nm. O.D. was measured in a microplate
reader (Tecan). Total amount of protein in samples were
measured using Bio-Rad protein assay kit (Bio-Rad, CA,
USA). All results were normalized to the total amount of
protein in each sample.
Fig. 1 Inhibitory effect of Buja on cold and mechanical allodynia in
oxaliplatin-injected rats. a Time course of tail withdrawal latency
(TWL) in response to cold water (4 °C) stimuli. An oxaliplatin injection
(group3: Oxaliplatin + DW) induced a significant decrease in TWL
since day 3 (D + 3) compared to a vehicle injection (group1: Vehicle
+ DW). Daily oral administration of Buja (300 mg/kg) for 5 days
following an oxaliplatin injection (group4: Oxaliplatin + Buja) significantly
inhibited cold allodynia, whereas Buja had no effect on TWL in
vehicle-injected rats (group2: Vehicle + Buja). b Time course of
mechanical threshold. An oxaliplatin injection (group3) significantly
decreased 50% threshold since day 3 compared to a vehicle injection
(group1). Buja administration following an oxaliplatin injection (group4)
significantly inhibited mechanical allodynia, whereas Buja had no effect
on mechanical threshold in vehicle-injected rats (group2). N = 6 rats/
group. Data are presented as mean ± SEM. * p < 0.05, *** p < 0.001, vs.
group1; ### p < 0.001, vs. group3, by two-way ANOVA followed by
Bonferroni’s post-test
Jung et al. BMC Complementary and Alternative Medicine  (2017) 17:48 Page 4 of 8Statistical analysis
All the data are presented as mean ± SEM (standard
error of the mean). Statistical analysis and graphic works
were performed with Prism 5.0 (GraphPad software,
USA). One-way analysis of variance (ANOVA) or
Two-way ANOVA followed by Bonferroni’s multiple
comparison test was used for statistical analysis. In all
cases, p < 0.05 was considered significant.
Results
Anti-allodynic effects of Buja in oxaliplatin-injected rats
To investigate whether Buja alleviates oxaliplatin-
induced neuropathic pain, cold and mechanical allodynia
were assessed using tail immersion test and von Frey
hair test, respectively, in randomly divided 4 groups of
animals (see Methods). Significant cold allodynia sign
(i.e. decreased TWL in response to cold stimuli) was
observed since day 3 after an oxaliplatin (6 mg/kg, i.p.)
injection (p < 0.05 at D + 3, p < 0.001 at D + 5, group1 vs.
group3, Fig. 1a). Daily oral dministration of Buja
(300 mg/kg) for 5 consecutive days following an oxali-
platin injection reversed such decrease in TWL to nor-
mal level (p < 0.001 at D + 5, group3 vs. group4, Fig. 1a).
For mechanical allodynia, an oxaliplatin injection
induced a significant decrease in 50% threshold since
day 3 (p < 0.001 at D + 3 and D + 5, group1 vs. group3,
Fig. 1b). Buja administration also reversed this mech-
anical allodynia sign to normal level (p < 0.001 at D +
3 and D + 5, group3 vs. group4, Fig. 1b). Buja admin-
istration in vehicle-injected rats (group2) showed no
effect on behavioral responses to cold and mechanical
stimuli (p > 0.05, vs group1, Fig. 1a and b). These re-
sults suggest that oral administration of Buja potently
inhibits oxaliplatin-induced cold and mechanical
allodynia in rats.
Suppressive effect of Buja on activation of spinal astrocytes
in oxaliplatin-injected rats
To determine whether Buja suppresses glial activation
in the dorsal horn of spinal cord after an oxaliplatin
injection, activation of spinal glial cells (i.e. astrocytes
and microglia) in laminae I-II of the dorsal horn was
quantified using immunohistochemical analysis. As
shown in Fig. 2, an oxaliplatin injection significantly
increased GFAP-positive cells (astrocytes) in the
spinal dorsal horn (p < 0.001, group1 vs. group3) and
these cells in the group3 exhibited somatic hyper-
trophy with thick processes (Fig. 2a), which is also
represented by enhanced intensity of immunoreactivity
(Additional file 1: Figure S2), indicating oxaliplatin-
induced activation of spinal astrocytes. Administration
of Buja significantly reduced such activation of spinal
astrocytes following an oxaliplatin injection (p < 0.001,
group3 vs. group4, Fig. 2). Co-immunolabelings ofGFAP (astrocytes) and Iba-1 (microglia) positive cells
in the same spinal cord samples were performed and
these cells were not co-localized (Additional file 2:
Figure S3). The number of Iba-I positive cells (micro-
glia) in the spinal dorsal horn is also increased fol-
lowing an oxaliplatin injection (p < 0.001, group1 vs.
group3, Additional file 3: Figure S1) and these cells in
the group3 showed amoeboid shapes with thick
processes (Additional file 3: Figure S1A), which is
Fig. 2 Buja attenuates the activation of spinal astrocytes in oxaliplatin-
injected rats. A Representative images of GFAP positive cells in the spinal
dorsal horn of group1: Vehicle + DW (a), group2: Vehicle + Buja (b),
group3: Oxaliplatin + DW (c) and group4: Oxaliplatin + Buja (d). Note the
increased number of GFAP positive cells and the altered morphology
(somatic hypertrophy with thick processes) in the group3 (c), indicating
activation of astrocytes. B Quantification result of GFAP positive cells. Six
lumbar spinal cord section images from single animal were averaged.
N= 6 rats/group. Data are presented as mean ± SEM. *** p< 0.001, vs.
group1; ### p< 0.001, vs. group3, by one-way ANOVA followed by
Bonferroni’s post-test
Fig. 3 Buja suppresses the oxaliplatin-induced up-regulation of spinal
pro-inflammatory cytokines. a, b Quantification of pro-inflammatory
cytokines, IL-1β (a) and TNF-α (b), in the spinal cord. N = 6 rats/group.
Data are presented as mean ± SEM. * p < 0.05, *** p < 0.001, vs. group1;
## p < 0.01, ### p < 0.001, vs. group3, by one-way ANOVA followed by
Bonferroni’s post-test. group1: Vehicle + DW, group2: Vehicle + Buja,
group3: Oxaliplatin + DW and group4: Oxaliplatin + Buja
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ity (Additional file 1: Figure S2). However, Buja
administration did not change such microglial activa-
tion, i.e. increased Iba-1 positive cells and altered
morphology (p > 0.05, group3 vs. group4, Additional
file 3: Figure S1). These results suggest that Buja sup-
presses activation of astrocytes in the spinal dorsal
horn following an oxaliplatin injection without affect-
ing microglial activation.Buja down-regulates the levels of spinal pro-
inflammatory cytokines in oxaliplatin-injected rats
Pro-inflammatory cytokines, IL-1β and TNF-α, were mea-
sured with ELISA carried out at the end of the experiment
(day 5). As shown in Fig. 3, the levels of IL-1β and TNF-α
in the spinal cord were significantly increased after an
oxaliplatin injection (p < 0.001 for IL-1β, p < 0.05 for
TNF-α, group1 vs. group3). Treatment of Buja reversed
this up-regulation of IL-1β and TNF-α in the spinal cord
to normal level (p < 0.001 for IL-1β, p < 0.01 for TNF-α,
group3 vs. group4). These results suggest that Buja can
suppress the oxaliplatin-induced increase in the levels of
spinal pro-inflammatory cytokines.
Discussion
Oxaliplatin, a widely used chemotherapeutic agent, is
known to evoke peripheral neuropathy even after a sin-
gle injection [1–3, 25]. Various kinds of experiments are
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oxaliplatin-induced peripheral neuropathy and its
optimal treatment method has not been developed yet
[23, 38]. Although its exact pathophysiology is not
clearly understood [23], accumulating evidences imply
that activation of spinal glia, such as astrocytes and
microglia, play an important role in oxaliplatin-induced
neuropathic pain [21, 22, 25, 39]. Activated spinal glia
were observed after oxaliplatin injection, and intrathecal
injection of minocycline and fluorocitrate, which de-
crease the activation of astrocytes and microglia respect-
ively, effectively attenuated neuropathic pain [22].
Activated glia are known to contribute to neuropathic
pain by releasing pro-inflammatory cytokines such as
IL-1β and TNF-α [13–15], and suppressing the activa-
tion of astrocytes and microglia down-regulated the
expression of pro-inflammatory cytokines, which led to
the alleviation of nerve injury-induced neuropathic pain
[40, 41]. Intrathecal injection of pro-inflammatory cyto-
kines such as IL-1β and TNF-α evoked hyperalgesia and
allodynia in naive animals [42, 43]. Furthermore, block-
ing the action of IL-1β and TNF-α using IL-1 receptor
antagonist and anti-TNF serum alleviated nerve injury-
induced neuropathic pain [44, 45]. In an animal model of
oxaliplatin-induced neuropathic pain, release of IL-1β and
TNF-α from activated spinal glia were observed [39, 46].
Intrathecally injected A3 adenosine receptor agonists pre-
vented the activation of astrocytes and the increase of
pro-inflammatory cytokines in the spinal cord and signifi-
cantly attenuated neuropathic pain [46]. Therefore, target-
ing spinal glial activation and pro-inflammatory cytokines
could be an ideal strategy to attenuate oxaliplatin-induced
neuropathic pain.
Buja is a generally used herbal medicine in East-Asia,
such as Korea, Japan and China. It is also a key compo-
nent in GBT, which has been traditionally used against
cold-induced disorders based on the Sang Han Lun [25].
In addition, GBT showed anti-allodynic effect on
oxaliplatin-induced neuropathic pain [25]. Recent exper-
iments conducted on both human and animals have
shown that Buja significantly improved cold or mechan-
ical allodynia [26, 28, 30]. In the present study, five con-
secutive oral administrations of Buja (300 mg kg−1 per
day) markedly alleviated oxaliplatin-induced cold and
mechanical allodynia. These results strongly suggest that
Buja has potent efficacy on oxaliplatin-induced neuro-
pathic pain.
Our experiment showed that oral administration of
Buja decreased the cold and mechanical allodynia via
suppressing the activation of spinal astrocytes. This
result is similar to that of Shibata et al. [26] where, Buja
was suggested to control neuropathic pain via inhibition
of activated astrocytes in nerve injury model. In neuro-
pathic state, extracellular single-regulated kinase (ERK)pathways in astrocytes were activated by IL-1β and
IL-18 from microglia and promoted the synthesis of
pro-inflammatory cytokines, IL-1β and TNF-α [47, 48].
Buja directly affected inhibition of ERK 1/2-phosphorla-
tion, which resulted in suppression of the spinal astro-
cytes [26]. However, in our previous study conducted
with GBT (400 mg kg−1 for five days), GBT attenuated
oxaliplatin-induced cold and mechanical allodynia by de-
creasing the activation of both spinal astrocytes and
microglia [25]. Although both Buja and GBT alleviated
oxaliplatin-induced cold and mechanical allodynia, Buja
only attenuated the activation of spinal astrocytes,
whereas GBT suppressed the activation of both astro-
cytes and microglia. Lorenzo et al. [22] mentioned that
although the activation of both spinal astrocytes and
microglia are important in oxaliplatin-induced neuro-
pathic pain, down-regulating only astrocytes or microglia
can lead to the attenuation of pain. In the action of sup-
pressing the activated glia by GBT, activated astrocytes
inhibition is achieved by Buja, and another component
of GBT may be responsible for the attenuation of micro-
glia. If any single medicinal herb, which has key effect, is
omitted, a specific activity from complex formulas disap-
pears [49]. Furthermore, studies of another component
in GBT are on the progress.
Pro-inflammatory cytokines, such as IL-1β and TNF-α,
released from activated glia, act on the spinal dorsal
horn neurons and influence excitatory neurotransmis-
sions [14, 15]. IL-1β, by inducing the phosphorylation of
a specific N-methyl-D-aspartate (NMDA) receptor sub-
unit, increases the influx of calcium ion through NMDA
receptor channel and the production of nitric oxide.
IL-1β also increases the generation of prostaglandin E2,
which amplify the excitability of pain-projection neurons
[14]. TNF-α, by enhancing the activation of α-Amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor, increases the excitatory post-synaptic currents
frequency in the spinal dorsal horn [20]. These interac-
tions between cytokines and neurons contribute to cen-
tral sensitization [50] and further enhance neuropathic
pain. In our result, the suppression of activated spinal
astrocytes and the decrease of IL-1β and TNF-α levels in
the spinal cord were coincided after treatment of Buja.
GBT also down-regulated release of spinal pro-
inflammatory cytokines [51]. Taken all together, our
findings suggest that Buja strongly alleviate oxaliplatin-
induced cold and mechanical allodynia via suppression
of activated spinal astrocytes and down-regulation of
pro-inflammatory cytokines.
Conclusion
In conclusion, this study clearly demonstrated the reliev-
ing effect of Buja on oxaliplatin-induced cold and mech-
anical allodynia. Also, Buja significantly suppressed the
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inflammatory cytokines after an oxaliplatin injection.
These results altogether suggest that Buja may be an
effective alternative to treat oxaliplatin-induced neuro-
pathic pain.
Additional files
Additional file 1: Figure S2. Intensity of immunoreactivity (IM) of GFAP
and Iba-1 positive cells. Intensity of IM of GFAP and Iba-1 positive cells
increased in group3. In group4, IM of GFAP positive cells were significantly
decreased, whereas little changes of Iba-1 positive cells IM was observed.
Data indicate that relative mean immunofluorescence intensity of a single
cell (n = 10). Data are presented as mean ± SEM. *** p < 0.001, vs. group1;
### p < 0.001, vs. group3, by one-way ANOVA followed by Bonferroni’s post-
test. group1: Vehicle + DW, group2: Vehicle + Buja, group3: Oxaliplatin + DW
and group4: Oxaliplatin + Buja. (PDF 7 kb)
Additional file 2: Figure S3. Representative co-immunolabeling image
of GFAP and Iba-1 positive cells in the spinal dorsal horn. Co-immunolabeling
in the same section showed the spatially different distribution of astrocytes
(GFAP-positive cells) and microglia (Iba-1 positive cells) in the spinal dorsal
horn (a). Separated images for astrocytes (b) and microglia (c) were also
presented, respectively. (PDF 236 kb)
Additional file 3: Figure S1. Spinal microglia activation was not
suppressed by Buja. (A) Representative images of Iba-1 positive cells in the
spinal dorsal horn of group1: Vehicle + DW (a), group2: Vehicle + Buja (b),
group3: Oxaliplatin +DW (c) and group4: Oxaliplatin + Buja (d). Note the
increased number of Iba-1 positive cells and the altered morphology (somatic
hypertrophy with thick processes) in the group3 (c), indicating activation of
microglia. (B) Quantification result of Iba-1 positive cells. Six lumbar spinal cord
section images from single animal were averaged. N= 6 rats/group. Data are
presented as mean ± SEM. *** p< 0.001, vs. group1; ### p< 0.001, vs. group3,
by one-way ANOVA followed by Bonferroni’s post-test. (PDF 260 kb)
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mAbs: Monoclonal antibodies; NMDA: N-methyl-D-aspartate; O.D.: Optical
density; OCT: Optimal cutting temperature; PBS: Phosphate buffered saline;
PBST: Phosphate buffered saline with Tween 20; RT: Room temperature; SD
rat: Sprauge-Dawley rat; SEM: Standard error and mean; TNF-α: Tumor necrosis
factor-α; TWL: Tail withdrawal latency
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